165 related articles for article (PubMed ID: 9438863)
41. Dissection of the nucleotide and metal-phosphate binding sites in cAMP-dependent protein kinase.
Herberg FW; Doyle ML; Cox S; Taylor SS
Biochemistry; 1999 May; 38(19):6352-60. PubMed ID: 10320366
[TBL] [Abstract][Full Text] [Related]
42. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
43. A structural model of the catalytic subunit-regulatory subunit dimeric complex of the cAMP-dependent protein kinase.
Tung CS; Walsh DA; Trewhella J
J Biol Chem; 2002 Apr; 277(14):12423-31. PubMed ID: 11799117
[TBL] [Abstract][Full Text] [Related]
44. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT).
Gassel M; Breitenlechner CB; Rüger P; Jucknischke U; Schneider T; Huber R; Bossemeyer D; Engh RA
J Mol Biol; 2003 Jun; 329(5):1021-34. PubMed ID: 12798691
[TBL] [Abstract][Full Text] [Related]
45. Catalytic subunit of cAMP-dependent protein kinase: electrostatic features and peptide recognition.
Tsigelny I; Grant BD; Taylor SS; Ten Eyck LF
Biopolymers; 1996 Sep; 39(3):353-65. PubMed ID: 8756515
[TBL] [Abstract][Full Text] [Related]
46. Accounting for global protein deformability during protein-protein and protein-ligand docking.
May A; Zacharias M
Biochim Biophys Acta; 2005 Dec; 1754(1-2):225-31. PubMed ID: 16214429
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of activation of cAMP-dependent protein kinase: in Mucor rouxii the apparent specific activity of the cAMP-activated holoenzyme is different than that of its free catalytic subunit.
Zaremberg V; Donella-Deana A; Moreno S
Arch Biochem Biophys; 2000 Sep; 381(1):74-82. PubMed ID: 11019822
[TBL] [Abstract][Full Text] [Related]
48. Biochemical characterization of galloyl pedunculagin (ellagitannin) as a selective inhibitor of the beta-regulatory subunit of A-kinase in vitro.
Kosuge S; Maekawa T; Saito C; Tanaka T; Kouno I; Ohtsuki K
J Biochem; 2001 Mar; 129(3):403-9. PubMed ID: 11226880
[TBL] [Abstract][Full Text] [Related]
49. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.
Trumpp-Kallmeyer S; Rubin JR; Humblet C; Hamby JM; Showalter HD
J Med Chem; 1998 May; 41(11):1752-63. PubMed ID: 9599227
[TBL] [Abstract][Full Text] [Related]
50. Dynamics of signaling by PKA.
Taylor SS; Kim C; Vigil D; Haste NM; Yang J; Wu J; Anand GS
Biochim Biophys Acta; 2005 Dec; 1754(1-2):25-37. PubMed ID: 16214430
[TBL] [Abstract][Full Text] [Related]
51. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.
Brown K; Long JM; Vial SC; Dedi N; Dunster NJ; Renwick SB; Tanner AJ; Frantz JD; Fleming MA; Cheetham GM
J Biol Chem; 2004 Apr; 279(18):18727-32. PubMed ID: 14766749
[TBL] [Abstract][Full Text] [Related]
52. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase.
Madhusudan ; Akamine P; Xuong NH; Taylor SS
Nat Struct Biol; 2002 Apr; 9(4):273-7. PubMed ID: 11896404
[TBL] [Abstract][Full Text] [Related]
53. Phosphorylation modulates catalytic function and regulation in the cAMP-dependent protein kinase.
Adams JA; McGlone ML; Gibson R; Taylor SS
Biochemistry; 1995 Feb; 34(8):2447-54. PubMed ID: 7873523
[TBL] [Abstract][Full Text] [Related]
54. The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
Alexeeva M; Åberg E; Engh RA; Rothweiler U
Acta Crystallogr D Biol Crystallogr; 2015 May; 71(Pt 5):1207-15. PubMed ID: 25945585
[TBL] [Abstract][Full Text] [Related]
55. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.
Meggio F; Donella Deana A; Ruzzene M; Brunati AM; Cesaro L; Guerra B; Meyer T; Mett H; Fabbro D; Furet P
Eur J Biochem; 1995 Nov; 234(1):317-22. PubMed ID: 8529658
[TBL] [Abstract][Full Text] [Related]
56. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.
Anderson K; Yang J; Koretke K; Nurse K; Calamari A; Kirkpatrick RB; Patrick D; Silva D; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2007 Sep; 46(36):10287-95. PubMed ID: 17705509
[TBL] [Abstract][Full Text] [Related]
57. Conformational differences among solution structures of the type Ialpha, IIalpha and IIbeta protein kinase A regulatory subunit homodimers: role of the linker regions.
Vigil D; Blumenthal DK; Heller WT; Brown S; Canaves JM; Taylor SS; Trewhella J
J Mol Biol; 2004 Apr; 337(5):1183-94. PubMed ID: 15046986
[TBL] [Abstract][Full Text] [Related]
58. Isoleucine 368 is involved in low-affinity binding of N6-modified cAMP analogues to site B of the regulatory subunit of cAMP-dependent protein kinase I.
Huq I; Dostmann WR; Ogreid D
Biochem J; 1996 May; 316 ( Pt 1)(Pt 1):337-43. PubMed ID: 8645227
[TBL] [Abstract][Full Text] [Related]
59. Tethering small molecules to a phage display library: discovery of a selective bivalent inhibitor of protein kinase A.
Meyer SC; Shomin CD; Gaj T; Ghosh I
J Am Chem Soc; 2007 Nov; 129(45):13812-3. PubMed ID: 17944472
[No Abstract] [Full Text] [Related]
60. Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements.
Defranchi E; Schalon C; Messa M; Onofri F; Benfenati F; Rognan D
PLoS One; 2010 Aug; 5(8):e12214. PubMed ID: 20808948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
